[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-001", "question": "A 14-month-old boy with genetically confirmed PMM2-CDG (p.Arg141His and p.Phe119Leu compound heterozygous variants) is scheduled for inguinal hernia repair. Preoperative coagulation studies show antithrombin III 45% (normal 80-120%), protein C 38% (normal 70-140%), and protein S 32% (normal 65-140%). All other labs are normal. What is the most appropriate perioperative management to minimize thrombotic risk?", "options": ["Proceed with surgery without prophylaxis; risk is theoretical", "Administer prophylactic enoxaparin 0.5 mg/kg subcutaneously 12 hours preoperatively and postoperatively", "Transfuse fresh frozen plasma to correct factor deficiencies before surgery", "Delay surgery indefinitely until coagulation factors normalize with nutritional support", "Administer antithrombin III concentrate 50 IU/kg immediately preoperatively"], "answer": "B", "answer_index": 1, "explanation": "PMM2-CDG causes combined antithrombin III, protein C, and protein S deficiency, creating significant thrombotic risk. For surgical prophylaxis, LMWH is recommended to address all deficient pathways. FFP provides insufficient correction and risks volume overload. ATIII concentrate alone doesn't address protein C/S deficiency. The thrombosis risk is not theoretical, with rates of 10-15% in moderate-severe cases.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "C", "model_outputs": "PMM2-CDG is associated with a hypercoagulable state due to deficiencies of antithrombin III, protein C, and protein S.  \nPerioperative thrombotic risk is significant, and fresh frozen plasma (FFP) is often used to replace these natural anticoagulants before surgery when concentrates are not available.  \nAntithrombin III concentrate would correct only one deficiency, leaving protein C and S deficiencies uncorrected.  \nEnoxaparin prophylaxis alone may be insufficient given the severity of the multiple anticoagulant factor deficiencies, and delaying surgery is not appropriate because these deficiencies do not normalize with nutritional support in PMM2-CDG.  \n\nThe most appropriate measure to minimize thrombotic risk in this setting is to replace all deficient factors via FFP transfusion preoperatively.  \n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-002", "question": "A 26-year-old woman ingests 60 mg of colchicine in a suicide attempt, presenting 8 hours later with profuse vomiting and diarrhea. Labs: WBC 22,000/μL, platelets 600,000/μL. Which intervention, when initiated within 12 hours of ingestion, has demonstrated mortality reduction in severe colchicine poisoning?", "options": ["Colchicine-specific Fab fragments 4 g IV bolus", "Granulocyte colony-stimulating factor 5 μg/kg/day subcutaneously", "Continuous venovenous hemofiltration at 50 mL/kg/hour", "N-acetylcysteine 150 mg/kg IV loading dose", "Plasma exchange daily for 5 days"], "answer": "B", "answer_index": 1, "explanation": "Early G-CSF administration reduces mortality by preventing septic complications from bone marrow suppression that begins 24-48 hours post-ingestion. Colchicine Fab (A) is experimental and unavailable. CVVH (C) does not enhance colchicine clearance due to large volume of distribution. NAC (D) has no role. Plasma exchange (E) is ineffective for intracellular toxins.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "A", "model_outputs": "Colchicine-specific Fab fragments have been reported in case reports and small series to dramatically reduce mortality in severe, life-threatening colchicine overdose when given early (within hours of ingestion).  \nThe other options (G-CSF, CVVH, NAC, plasma exchange) are either not specific or lack evidence for mortality reduction in this setting.  \n\nThe answer is (A)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-003", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "gynecology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "B", "model_outputs": "The clinical and pathological features fit **placental site trophoblastic tumor (PSTT)**:  \n- Presentation months or years after pregnancy (here, 18 months after delivery).  \n- Mild elevation of hCG (often less than in choriocarcinoma).  \n- Intrauterine mass on imaging.  \n- Biopsy shows sheets of intermediate trophoblast cells with eosinophilic cytoplasm, low mitotic index, strong staining for hPL (human placental lactogen) and minimal hCG staining on IHC, which is characteristic of PSTT.  \n- Choriocarcinoma stains strongly for hCG, has biphasic pattern, and high mitotic activity; epithelioid trophoblastic tumor is more like carcinoma but also p63 positive; hydatidiform/invasive mole have villous structures.  \n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-004", "question": "A 28-year-old male with a dibucaine number of 20 (normal >70) and pseudocholinesterase activity of 0.2 U/mL (normal 0.5-1.2) requires emergency intubation for airway obstruction. After succinylcholine 1.5 mg/kg, apnea persists for 90 minutes. Which anesthetic agent should be avoided in future surgeries due to shared metabolic pathway?", "options": ["Rocuronium", "Ester local anesthetics (procaine, chloroprocaine)", "Vecuronium", "Cisatracurium", "Remifentanil"], "answer": "B", "answer_index": 1, "explanation": "A dibucaine number of 20 indicates homozygous atypical pseudocholinesterase. Succinylcholine and ester local anesthetics (procaine, chloroprocaine, tetracaine) are both metabolized by pseudocholinesterase. Aminosteroid relaxants (rocuronium, vecuronium) and benzylisoquinoliniums (cisatracurium) are not metabolized by this enzyme. Remifentanil is metabolized by non-specific esterases and is safe.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "abms_specialty": "Anesthesiology", "abms_source": "target_topic", "source_label_raw": "Anesthesiology", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-006", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "B", "model_outputs": "The dibucaine number and low pseudocholinesterase activity indicate the patient has atypical pseudocholinesterase, which prolongs the action of succinylcholine and also hydrolyzes ester-type local anesthetics such as procaine and chloroprocaine.  \nThus, in future surgeries, ester local anesthetics should be avoided because they share this metabolic pathway and could have prolonged effects.  \n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-005", "question": "A 22-year-old female with systemic lupus erythematosus presents with nihilistic delusions that her organs have 'turned to dust' and that she is already dead. CSF shows lymphocytic pleocytosis and elevated protein. Which specific autoantibody is most strongly associated with this neuropsychiatric manifestation?", "options": ["Anti-dsDNA", "Anti-NR2A (NMDA receptor)", "Anti-Ro/SSA", "Anti-phospholipid", "Anti-Sm"], "answer": "B", "answer_index": 1, "explanation": "Anti-NR2A antibodies targeting NMDA receptors correlate strongly with diffuse neuropsychiatric SLE manifestations including psychosis, delusional states, and cognitive dysfunction. Anti-dsDNA is a general SLE marker without specific neuropsychiatric correlation. Anti-Ro is associated with neonatal lupus. Antiphospholipid antibodies cause thrombotic events. Anti-Sm is specific for SLE but not associated with particular neuropsychiatric features.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "B", "model_outputs": "The neuropsychiatric presentation described (nihilistic delusions including Cotard’s syndrome — “already dead”) with CSF findings (lymphocytic pleocytosis, elevated protein) is highly suggestive of autoimmune encephalitis related to anti-NMDA receptor antibodies.  \nAnti-NR2A antibodies target the NMDA receptor and have been specifically linked to neuropsychiatric lupus, especially in cases with diffuse CNS symptoms resembling autoimmune encephalitis.\n\nA. Anti-dsDNA — associated with lupus nephritis, not specific to this neuropsychiatric presentation.  \nB. Anti-NR2A (NMDA receptor) — direct pathogenic link to psychosis, memory deficits, and encephalitis in SLE.  \nC. Anti-Ro/SSA — associated with cutaneous and neonatal lupus, Sjögren's syndrome.  \nD. Anti-phospholipid — associated with vascular thrombosis, not this encephalitic presentation.  \nE. Anti-Sm — specific for SLE but associated with renal disease, not this specific CNS syndrome.  \n\nTherefore, anti-NR2A is most strongly associated with this manifestation.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-006", "question": "A 58-year-old man with mid-rectal cancer (cT3N1M0) has enlarged right obturator lymph node (8 mm) on staging MRI. The primary tumor is 5 cm from the anal verge. What is the optimal treatment sequence?", "options": ["A) Long-course chemoradiation (50.4 Gy) followed by total mesorectal excision without lateral dissection", "B) Short-course radiation (25 Gy) followed by extended lymphadenectomy including obturator nodes", "C) Chemoradiation (50.4 Gy) with boost to obturator node, then TME with selective lateral dissection if node persists", "D) Induction chemotherapy (FOLFOX) followed by chemoradiation and TME", "E) Total neoadjuvant therapy with consolidation chemotherapy then TME with bilateral lateral lymph node dissection"], "answer": "C", "answer_index": 2, "explanation": "For rectal cancer with suspicious lateral lymph node, chemoradiation with simultaneous integrated boost (60 Gy to node) followed by TME with selective lateral dissection only for radiologically persistent nodes balances local control and morbidity. Prophylactic lateral dissection causes unnecessary urinary and sexual dysfunction. The Japanese JCOG0212 trial showed selective dissection is non-inferior to routine dissection when nodes respond to radiation.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "abms_specialty": "General Surgery", "abms_source": "target_topic", "source_label_raw": "General Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-011", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "C", "model_outputs": "The patient has a locally advanced mid-rectal cancer (cT3N1) with an enlarged right obturator lymph node (8 mm) on MRI.  \nObturator nodes are considered lateral pelvic lymph nodes (LPLNs).  \nFor rectal cancer with clinically involved lateral lymph nodes, current guidelines (such as NCCN and ESMO) often recommend chemoradiation (50.4 Gy) with coverage of the involved lateral nodal basin, followed by reassessment and consideration of lateral lymph node dissection if the node remains enlarged or suspicious after chemoradiation.  \n\nOption C describes:  \n- Chemoradiation (50.4 Gy) with a boost to the obturator node  \n- Then TME with selective lateral dissection if the node persists  \n\nThis matches the modern selective approach for lateral nodal disease in rectal cancer, avoiding routine extensive lateral dissection upfront if chemoradiation may sterilize the node, but planning dissection if it persists.  \n\nThe answer is C"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-007", "question": "A 3-year-old child with bilateral retinoblastoma has persistent class 3 vitreous seeds (vitreous clouds) in the right eye after six cycles of systemic chemotherapy and three intravitreal melphalan injections (30 µg). Examination shows tumor regression but diffuse non-confluent vitreous opacities. What is the next definitive management step?", "options": ["A) Increase intravitreal melphalan dose to 50 µg weekly for three doses", "B) Plaque brachytherapy with 125I to deliver 40 Gy to vitreous base", "C) Enucleation with histopathologic risk factor assessment", "D) Intravitreal topotecan 20 µg alternating with melphalan every 2 weeks", "E) External beam radiation therapy 45 Gy to entire globe"], "answer": "D", "answer_index": 3, "explanation": "For persistent class 3 vitreous seeds after standard melphalan, alternating intravitreal topotecan with melphalan provides synergistic tumoricidal activity while avoiding retinal toxicity from dose escalation. This protocol achieves 85% globe salvage for refractory seeds compared to 40% with continued melphalan alone, and avoids the late effects of external beam radiation in hereditary retinoblastoma.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "abms_specialty": "Ophthalmology", "abms_source": "target_topic", "source_label_raw": "Ophthalmology", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "C", "model_outputs": "In refractory retinoblastoma with persistent class 3 vitreous seeds after systemic chemotherapy and intravitreal melphalan, the seeds remain a high risk for relapse and metastasis. If viable tumor persists and there is concern for chemoresistance, definitive treatment to prevent extraocular spread becomes necessary.  \nGiven the bilateral disease, salvaging the eye may be attempted if feasible, but after multiple intravitreal injections and systemic therapy without adequate response, the risk of losing the eye to progressive disease and metastasis outweighs further conservative measures. Enucleation allows for histopathologic assessment of risk factors (such as optic nerve invasion, choroidal invasion) to guide adjuvant therapy and reduces the metastatic risk.  \n\nOther options:  \n- Increasing intravitreal melphalan dose (A) or adding topotecan (D) risks toxicity and may not control resistant disease.  \n- Plaque brachytherapy (B) is not effective for diffuse vitreous seeds.  \n- External beam radiotherapy (E) is avoided in young children due to secondary malignancy risk in retinoblastoma survivors, especially with germline RB1 mutation (likely here due to bilateral disease).  \n\nThus, the next definitive step after failed conservative therapy is enucleation.  \n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-008", "question": "A 78-year-old woman falls and sustains a four-part proximal humerus fracture with head-split pattern and 2 cm medial calcar comminution. The greater tuberosity is fractured but not displaced. What is the optimal implant selection?", "options": ["A) Open reduction and internal fixation with locking plate and fibular allograft augmentation", "B) Hemiarthroplasty with cemented stem and tuberosity repair", "C) Reverse shoulder arthroplasty with 36 mm glenosphere and augmented baseplate", "D) Reverse shoulder arthroplasty with standard baseplate and tuberosity preservation", "E) Nonoperative management with sling and early passive motion"], "answer": "D", "answer_index": 3, "explanation": "In elderly patients with head-split fractures and intact tuberosities, reverse shoulder arthroplasty with standard baseplate and tuberosity preservation (not repair) provides superior forward elevation and reduces prosthetic instability. Augmented baseplates are unnecessary without glenoid bone loss, and tuberosity repair in reverse arthroplasty increases stiffness without functional benefit. ORIF has 60% failure rate in this pattern, and hemiarthroplasty requires functional rotator cuff.", "generator_model": "kimi-k2-thinking", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Orthopedic Surgery", "abms_specialty": "Orthopedic Surgery", "abms_source": "target_topic", "source_label_raw": "Orthopedic Surgery", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed130", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed130-014", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed130", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed130.jsonl", "pred": "C", "model_outputs": "Let’s break this down:  \n\n- **Patient:** 78-year-old woman.  \n- **Injury:** Four-part proximal humerus fracture with **head-split pattern** and **2 cm medial calcar comminution**.  \n- **Greater tuberosity:** fractured but not displaced.  \n\n**Key factors:**  \n- Head-split fracture means the articular surface is fractured into pieces, making preservation of the humeral head unlikely.  \n- Medial calcar comminution (2 cm) means bony support for a conventional hemiarthroplasty is poor, risking tuberosity malunion/nonunion and poor function.  \n- In elderly patients with this pattern, reverse total shoulder arthroplasty (RSA) is generally preferred over hemiarthroplasty because it does not rely on tuberosity healing for functional overhead motion.  \n- Among RSA options:  \n  - **C** specifies augmented baseplate (useful if glenoid bone loss, but not explicitly mentioned here) and 36 mm glenosphere.  \n  - **D** specifies standard baseplate and tuberosity preservation (tuberosity is already fractured but not displaced; preservation/repair is still done, but standard baseplate may not address potential instability from medial bone loss).  \n- **Medial calcar comminution** may require a **fracture-specific RSA stem** with medial offset or augmentation to restore length and stability, but the options given don’t specify stems, just glenosphere/baseplate. Between C and D, the augmented baseplate in **C** might help compensate if there is glenoid wear, but the stem design matters more for calcar comminution. However, in many question contexts, for an elderly patient with head-split + calcar comminution, RSA is the answer, and between the RSA choices, the one with features addressing potential instability (augmented baseplate, larger glenosphere for stability) is often chosen.  \n\nGiven common teaching:  \n- Hemiarthroplasty (B) is less ideal due to tuberosity healing issues in elderly with medial calcar comminution.  \n- ORIF (A) is unlikely in a 78-year-old with head-split and significant comminution.  \n- Nonoperative (E) would likely lead to poor function.  \n\nBetween **C** and **D**, **C** (reverse shoulder arthroplasty with 36 mm glenosphere and augmented baseplate) is often the preferred answer in exam settings for complex fractures with bone loss, as it may improve stability and fixation.  \n\nThe answer is C.  \n\n**The answer is (C)**"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-009", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Critical Care Medicine", "abms_specialty": "Critical Care Medicine", "abms_source": "topics_mapped", "source_label_raw": "critical care", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed125", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed125.jsonl", "pred": "C", "model_outputs": "In severe hemolysis, free hemoglobin can interfere with **aPTT** and **ACT** assays by acting as a peroxidase that affects optical clot detection and by other mechanisms.  \nArgatroban is a direct thrombin inhibitor, so its effect is best measured by a **thrombin (IIa)-specific chromogenic assay**, which is not affected by hemolysis.  \nAnti-Xa assays are for factor Xa inhibitors (not argatroban).  \ndRVVT is mainly for lupus anticoagulant testing.  \n\nThe most reliable in this setting is therefore the **anti-IIa chromogenic assay**.  \n\nThe answer is (C)"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p01", "question_id": "ABMS20260101_kimi-k2-thinking_p01-010", "question": "A 42-year-old man with a heterozygous CSF1R p.Arg782His mutation and early-stage adult-onset leukoencephalopathy with axonal spheroids (ALSP) has mild cognitive impairment and gait instability. His sister progressed to severe dementia within 3 years of symptom onset. Which intervention has demonstrated the highest disease-modifying efficacy when performed before onset of severe motor disability?", "options": ["Intravenous immunoglobulin monthly", "Oral cyclophosphamide 2 mg/kg/day", "Allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor", "Ruxolitinib 20 mg twice daily", "Supportive care with donepezil"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic HSCT is the only intervention shown to halt ALSP progression when performed early, before severe disability, by replacing microglial precursors. IVIG (A) and cyclophosphamide (B) lack efficacy. Ruxolitinib (D) has no clinical data. Supportive care (E) does not modify disease course. Delay until severe motor impairment predicts transplant failure.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-002", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "C", "model_outputs": "Allogeneic hematopoietic stem cell transplantation (HSCT) has shown disease-modifying potential in early-stage ALSP (associated with CSF1R mutations) by replacing dysfunctional microglia, and studies suggest better outcomes if performed before severe motor disability develops. The other options are either supportive or not established as disease-modifying in ALSP.  \n\nThe answer is C"}]